Tau and Pet/Mri Imaging Biomarkers for Detecting and Diagnosing Early Dementia
Yongxia Zhou, Ph.D.*, Bing Bai, and For the Alzheimer’s Disease Neuroimaging Initiative
Specific objective of this project is to quantify the neuropathological tau depositions in brain regions and to investigate primary age-related tau pathology and associations with amyloid and glucose-metabolism, neurocognitive tests and MRI metrics. Preliminary results demonstrated higher temporal deposition especially in the hippocampus and the inferior temporal regions compared to mean cortical deposition. Quantitative Braak stage-based regional analyses found highest tau deposition in the Braak stage II in the preclinical samples.
Quantitative PET/MRI Evaluation and Application in Dementia
Yongxia Zhou, PhD*
A recently introduced integrated scanner combining simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) (PET/MRI) acquisition presents a unique set of opportunities for neuroimaging research and dementia in particular. Among these, the intrinsic co-registration of the images has the potential to reduce errors in multi-modality image registration, which could lead to better quantification of longitudinal volumetric changes in neuroanatomical features that are important for assessing disease progression. PET tracers could provide functional information of brain biochemical processes by radio-labeling specific molecular with high sensitivity and specificity, while MRI could provide superior structural information.